Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic Antibiotics for RFA in HCC
NCT02534961Phase 4Unknown
- Sponsor
- Taipei Veterans General Hospital
- Start
- Jan 2015
- Primary completion
- Dec 2017
- Modality
- Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of cefazolin in bacterial infection (2 arms), sponsored by Taipei Veterans General Hospital. Primary endpoint: Infection after radiofrequency ablation at 4 weeks. Status: unknown.
02
Drugs
cefazolin
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT02534961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02534961.